HEPATITIS: MicroRNA antagonists: promising antiviral agents against HCV and other viruses?
A new study provides an important proof-of-concept that viral replication can be substantially reduced for several weeks by a single injection of a tissue-targeted cellular microRNA antagonist, inhibiting a key component in a viral lifecycle. This result paves the way to the development of novel potent host-targeted antiviral approaches based on microRNA antagonism.
Refers to van der Ree, M. H. et al. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomized controlled trial. Lancet389, 709-717 (2017).